新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » 帕金森病 » Neurology:开发出治疗中风的新型骨髓干细胞疗法

Neurology:开发出治疗中风的新型骨髓干细胞疗法

来源:生物谷 2014-04-10 23:55

2014年4月10日 讯 /生物谷BIOON/ --近日,刊登在国际杂志Neurology上的一篇研究报告中,来自Bill Gross干细胞研究中心等处的研究人员通过研究表明,骨髓干细胞或许对于中风患者恢复具有很好的疗效。

文章中,神经学家Steven Cramer及其同事通过分析46项利用间质细胞来进行中风模型动物的研究,发现间充质干细胞(MSCs)对于中风模型动物具有较好的治疗效果,而且对动物模型机体细胞功能的恢复与MSCs的剂量无关。

Cramer表示,长期以来中风一直是导致个体残疾的主要原因,我们很高兴发现MSCs对治疗缺血性中风的作用,而且MSCs也是科学家们研究的重点,其来源于骨髓而且可以稳定获得、易于培养,其在治疗人类疾病上表现出了较大的潜力。

早期研究中,研究者重点关注了MSCs的作用原理,研究者发现MSCs可以促进中风后个体的大脑修复,MSCs可以吸附到受伤位点,对损伤区域产生的信号产生反应,并且开启修复机制。因此MSCs就具有多种活性,比如增强血液循环,保护脑部细胞等;当MSCs达到血液中后,其往往会在机体的某个部位上“定居”从而控制机体的免疫系统并且促使环境更加利于进行大脑修复。

最后研究者表示,MSCs具有持续性改善机体功能的作用,本文的研究为揭示MSCs在治疗人类中风上的作用提供了一定的思路,也为开发新型治疗中风的疗法提供了希望和帮助。(生物谷Bioon.com)

Meta-analysis of preclinical studies of mesenchymal stromal cells for ischemic stroke

Quynh Vu, BS*, Kate Xie, BA*, Mark Eckert, PhD, Weian Zhao, PhD and Steven C. Cramer, MD

Objectives: To evaluate the quality of preclinical evidence for mesenchymal stromal cell (MSC) treatment of ischemic stroke, determine effect size of MSC therapy, and identify clinical measures that correlate with differences in MSC effects. Methods: A literature search identified studies of MSCs in animal models of cerebral ischemia. For each, a Quality Score was derived, and effect size of MSCs was determined for the most common behavioral and histologic endpoints. Results: Of 46 studies, 44 reported that MSCs significantly improved outcome. The median Quality Score was 5.5 (of 10). The median effect size was 1.78 for modified Neurological Severity Score, 1.73 for the adhesive removal test, 1.02 for the rotarod test, and 0.93 for infarct volume reduction. Quality Score correlated significantly and positively with effect size for the modified Neurological Severity Score. Effect sizes varied significantly with clinical measures such as administration route (intracerebral > intra-arterial > IV, although effect size for IV was nonetheless very large at 1.55) and species receiving MSCs (primate > rat > mouse). Because many MSC mechanisms are restorative, analyses were repeated examining only the 36 preclinical studies administering MSCs ≥24 hours poststroke; results were overall very similar. Conclusions: In preclinical studies, MSCs have consistently improved multiple outcome measures, with very large effect sizes. Results were robust across species studied, administration route, species of MSC origin, timing, degree of immunogenicity, and dose, and in the presence of comorbidities. In contrast to meta-analyses of preclinical data for other stroke therapies, higher-quality MSC preclinical studies were associated with larger behavioral gains. These findings support the utility of further studies to translate MSCs in the treatment of ischemic stroke in humans.

温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库